このアイテムのアクセス数: 162
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| 25_0737.pdf | 361.11 kB | Adobe PDF | 見る/開く |
| タイトル: | 前立腺肥大症に対するTSAA-291の使用経験 |
| その他のタイトル: | CLINICAL EXPERIENCE WITH TSAA-291 FOR BENIGN PROSTATIC HYPERTROPHY |
| 著者: | 山元, 敏嗣  田中, 啓幹 高田, 元敬 |
| 著者名の別形: | Yamamoto, Toshiaki Tanaka, Hiroyoshi Takada, Motoyoshi |
| 発行日: | Jul-1979 |
| 出版者: | 京都大学医学部泌尿器科学教室 |
| 誌名: | 泌尿器科紀要 |
| 巻: | 25 |
| 号: | 7 |
| 開始ページ: | 737 |
| 終了ページ: | 745 |
| 抄録: | Nineteen patients of benign prostatic hypertrophy in our clinic (Stage I 13, Stage II 6) were treated with 16β-ethyl-17 β-hydroxy-4-estren-3-one(TSAA-291 ), a new strong anti-androgenic agent developed by Takeda Chemical Industries, Ltd. 200 mg/week of TSAA-291 were injected for 11 -12 weeks. Residual urine, dysuria, urinary stream, straining and nycturia were examined as to clinical effect. Clinical findings improved in 14 of 19 cases. Side effects were found in two patients, one was malaise, another one was headache and palpitation. Abnormal change in hemogram, liver function, renal function and serum acid-phosphatase after injection of TSAA-291 were not observed. In conclusion, TSAA-291 can be used without detectable side effects for conservative treatment of some selected cases of benign prostatic hypertrophy. |
| URI: | http://hdl.handle.net/2433/122457 |
| 出現コレクション: | Vol.25 No.7 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。